Last reviewed · How we verify
NCT07325500: REINFORCE
Incretin Microdosing for Cardiometabolic Health in People With HIV
Phase 2 trial testing Dose escalation to 2 mg semaglutide weekly then semaglutide microdosing at 0.5 mg weekly in Weight Gain in 30 participants. Currently enrolling.
31 May 2028
Quick facts
| Lead sponsor | The University of Texas Health Science Center, Houston |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 12 February 2026 |
| Primary completion | 31 May 2028 |
| Estimated completion | 30 June 2029 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Dose escalation to 2 mg semaglutide weekly then semaglutide microdosing at 0.5 mg weekly — full drug profile →
- Dose escalation to 2 mg semaglutide weekly then no semaglutide — full drug profile →
Conditions studied
- Weight Gain — all drugs for Weight Gain →
Sponsor
The University of Texas Health Science Center, Houston
Who can join
18 and older, any sex, with Weight Gain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objectives of this study are as follows: Primary Objective * To determine the rate of weight regain in people living with human immunodeficiency virus (HIV) (PWH) receiving semaglutide microdosing vs. no additional drug following induction therapy. Secondary Objectives * To evaluate the tolerability of semaglutide microdosing in adults with HIV. * To evaluate changes in weight, waist circumference (WC) and body mass index (BMI) over 12 weeks (W) of semaglutide weight loss induction and 48 W of semaglutide microdosing therapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07325500
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Weight Gain
Currently open trials in the same condition.
- NCT05652478 — Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study · Phase 2 · recruiting
- NCT07190170 — Time Restricted Eating for WeIght LoSs MainTenance-2 · NA · recruiting
- NCT06511310 — Exercise, Brain Activity, and Weight Maintenance · NA · recruiting
- NCT04252547 — Effect of Kangaroo Care on Test Weighing · NA · recruiting
- NCT05780814 — The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer · NA · recruiting
Other The University of Texas Health Science Center, Houston trials
Trials by the same sponsor.
- NCT04200729 — Povidone-iodine Irrigation for Prevention of Intra-abdominal Abscess in Pediatric Perforated Appendicitis: a Multi-cente · Phase 4 · not yet recruiting
- NCT07225062 — Improving HIV Prevention and Substance Use Post-Sexual Assault Services · NA · not yet recruiting
- NCT07396974 — Increasing Treatment Access in Trauma Exposed Children: Developing an Adapted Step One Intervention (RCT) · NA · not yet recruiting
- NCT07170163 — Navigating the Transition to Adulthood: A Dual Language Mobile App for Latino Youth With ASD and Their Families · NA · not yet recruiting
- NCT06915441 — Lipid Infusions to Optimize Nutrition Trial · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07325500 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The University of Texas Health Science Center, Houston
- Last refreshed: 18 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07325500.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing